We report on a patient with breast cancer in whom there were areas of the tumor that were 3+ positive and negative for HER2 neu by immunohistochemistry, adjacent to each other. Depending on the area tested the results were completely different. The clinical implications are important. We recommend retesting a large portion of the tumor in all cases of initially negative test results
BACKGROUND: The importance of human epidermal growth factor receptor 2 (HER2) as a prognostic and pr...
BACKGROUND: The ASCO/CAP guidance on HER2 testing in breast cancer (BC) has recently changed. Group ...
textabstractAims: Equivocal human epidermal growth factor receptor 2 protein (HER2) (2+) immunohisto...
CASE The patient is a 75 year-old female with a history of stage 1 invasive ductal carcinoma of the ...
Objective: HER2 status in breast cancer is an essential parameter in individual therapeutic decision...
Objectives: HER2/neu gene amplification by Fluorescent in situ hybridization and protein expression ...
BackgroundHER2/neu overexpression and/or amplification has been widely studied in a number of solid ...
Targeted therapy for patients with HER2‐positive (HER2+) breast cancer has improved overall survival...
Targeted therapy for patients with HER2‐positive (HER2+) breast cancer has improved overall survival...
Heterogeneous expression or amplification is a challenge to HER2 diagnostics. A guideline defines he...
BackgroundThe importance of human epidermal growth factor receptor 2 (HER2) as a prognostic and pred...
Background: Only 25 % of patients with HER-2/neu-positive metastatic breast tumors respond favorably...
Introduction: Breast cancer is a leading cause of concern in today’s medical care and newer diagnost...
Accurate assessment of HER -2 status is essential for identifying patients who will benefit from HER...
HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. ...
BACKGROUND: The importance of human epidermal growth factor receptor 2 (HER2) as a prognostic and pr...
BACKGROUND: The ASCO/CAP guidance on HER2 testing in breast cancer (BC) has recently changed. Group ...
textabstractAims: Equivocal human epidermal growth factor receptor 2 protein (HER2) (2+) immunohisto...
CASE The patient is a 75 year-old female with a history of stage 1 invasive ductal carcinoma of the ...
Objective: HER2 status in breast cancer is an essential parameter in individual therapeutic decision...
Objectives: HER2/neu gene amplification by Fluorescent in situ hybridization and protein expression ...
BackgroundHER2/neu overexpression and/or amplification has been widely studied in a number of solid ...
Targeted therapy for patients with HER2‐positive (HER2+) breast cancer has improved overall survival...
Targeted therapy for patients with HER2‐positive (HER2+) breast cancer has improved overall survival...
Heterogeneous expression or amplification is a challenge to HER2 diagnostics. A guideline defines he...
BackgroundThe importance of human epidermal growth factor receptor 2 (HER2) as a prognostic and pred...
Background: Only 25 % of patients with HER-2/neu-positive metastatic breast tumors respond favorably...
Introduction: Breast cancer is a leading cause of concern in today’s medical care and newer diagnost...
Accurate assessment of HER -2 status is essential for identifying patients who will benefit from HER...
HER2 is overexpressed in approximately 10%-20% of gastric and gastroesophageal junction carcinomas. ...
BACKGROUND: The importance of human epidermal growth factor receptor 2 (HER2) as a prognostic and pr...
BACKGROUND: The ASCO/CAP guidance on HER2 testing in breast cancer (BC) has recently changed. Group ...
textabstractAims: Equivocal human epidermal growth factor receptor 2 protein (HER2) (2+) immunohisto...